Zafgen Inc. (ZFGN) Stock Price Up 5.4%
Shares of Zafgen Inc. (NASDAQ:ZFGN) rose 5.4% during mid-day trading on Tuesday . The stock traded as high as $3.34 and last traded at $3.31, with a volume of 298,800 shares traded. The stock had previously closed at $3.14.
ZFGN has been the topic of several analyst reports. Cowen and Company reiterated a “buy” rating and set a $60.00 target price on shares of Zafgen in a report on Thursday, August 25th. Leerink Swann reiterated a “market perform” rating and set a $6.00 target price on shares of Zafgen in a report on Wednesday, July 20th. FBR & Co reiterated a “buy” rating on shares of Zafgen in a report on Monday, June 13th. Zacks Investment Research upgraded Zafgen from a “hold” rating to a “buy” rating and set a $3.50 target price on the stock in a report on Tuesday, July 26th. Finally, Canaccord Genuity set a $4.00 target price on Zafgen and gave the stock a “hold” rating in a report on Thursday, July 21st. Five research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Zafgen presently has a consensus rating of “Buy” and an average target price of $14.22.
The company’s 50-day moving average is $3.12 and its 200-day moving average is $5.44. The stock’s market cap is $91.74 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/zafgen-inc-zfgn-stock-price-up-5-4.html
In related news, CFO Patricia L. Allen purchased 16,000 shares of the business’s stock in a transaction on Tuesday, July 26th. The stock was acquired at an average price of $3.12 per share, for a total transaction of $49,920.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Thomas E. Hughes purchased 10,000 shares of the business’s stock in a transaction on Monday, August 29th. The shares were bought at an average price of $3.00 per share, with a total value of $30,000.00. Following the purchase, the insider now directly owns 63,936 shares in the company, valued at approximately $191,808. The disclosure for this purchase can be found here. Company insiders own 20.30% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in ZFGN. Alliancebernstein L.P. bought a new position in Zafgen during the second quarter worth about $114,000. Bellevue Group AG bought a new position in Zafgen during the first quarter worth about $134,000. ProShare Advisors LLC increased its position in Zafgen by 4.9% in the second quarter. ProShare Advisors LLC now owns 23,099 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 1,075 shares during the period. Rhumbline Advisers increased its position in Zafgen by 103.0% in the second quarter. Rhumbline Advisers now owns 34,692 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 17,602 shares during the period. Finally, Alps Advisors Inc. increased its position in Zafgen by 25.1% in the second quarter. Alps Advisors Inc. now owns 38,312 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 7,683 shares during the period. Institutional investors and hedge funds own 62.83% of the company’s stock.
Zafgen Company Profile
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.